| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PL | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI136272 | Development of highly potent human monoclonal for RSV immuno-prophylaxis | 000 | 5 | NIH | 4/9/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $916,445 ) |
| | 2022 | 2022 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI136272 | Development of highly potent human monoclonal for RSV immuno-prophylaxis | 000 | 5 | NIH | 6/15/2022 | $947,868 |
| | 2022 | 2019 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | SB1AI082744 | MR191_ An Immunoprotectant for Marburg Virus | 000 | 8 | NIH | 4/8/2022 | -$31,423 |
| | 2022 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 000 | 1 | NIH | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $768,169 ) |
| | 2021 | 2021 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI136272 | Development of highly potent human monoclonal for RSV immuno-prophylaxis | 001 | 4 | NIH | 7/8/2021 | $801,020 |
| | 2021 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 002 | 2 | NIH | 6/3/2021 | $32,851 |
| | 2021 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI136272 | Development of highly potent human monoclonal for RSV immuno-prophylaxis | 000 | 3 | NIH | 6/14/2021 | $58,549 |
| | 2021 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 003 | 2 | NIH | 6/24/2021 | -$32,851 |
| | 2021 | 2019 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R43AI136272 | Development of highly potent human monoclonals for RSV immunoprophylaxis | 000 | 2 | NIH | 6/14/2021 | -$58,549 |
| | 2021 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 4921 DIRECTORS PLACE STE 100 | SAN DIEGO | CA | 92121-3823 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 001 | 1 | NIH | 6/3/2021 | -$32,851 |
|
| Issue Date FY: 2020 ( Subtotal = $988,518 ) |
| | 2020 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI136272 | Development of highly potent human monoclonal for RSV immuno-prophylaxis | 001 | 3 | NIH | 7/20/2020 | -$1,175 |
| | 2020 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI136272 | Development of highly potent human monoclonal for RSV immuno-prophylaxis | 000 | 3 | NIH | 7/2/2020 | $1,000,000 |
| | 2020 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 002 | 2 | NIH | 8/11/2020 | -$924,471 |
| | 2020 | 2020 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 001 | 2 | NIH | 4/6/2020 | $924,471 |
| | 2020 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R01AI111391 | An Immunoprotectant for Argentine Hemorrhagic Fever | 000 | 5 | NIH | 9/28/2020 | $0 |
| | 2020 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 000 | 1 | NIH | 3/26/2020 | $0 |
| | 2020 | 2017 | Mapp Biopharmaceutical, Inc. | 6160 Lusk Blvd Ste 105 | San Diego | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 03 | 1 | CDC | 11/21/2019 | -$982 |
| | 2020 | 2017 | Mapp Biopharmaceutical, Inc. | 6160 Lusk Blvd Ste 105 | San Diego | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 03 | 1 | CDC | 11/21/2019 | -$9,325 |
|
| Issue Date FY: 2019 ( Subtotal = $1,077,529 ) |
| | 2019 | 2019 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | SB1AI082744 | MR191_ An Immunoprotectant for Marburg Virus | 000 | 8 | NIH | 6/12/2019 | $1,000,000 |
| | 2019 | 2019 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI136272 | Development of highly potent human monoclonals for RSV immunoprophylaxis | 000 | 2 | NIH | 12/28/2018 | $300,000 |
| | 2019 | 2017 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI129082 | Direct sequencing of serum antibodies after infection | 000 | 1 | NIH | 2/11/2019 | -$3,409 |
| | 2019 | 2016 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R01AI098774 | An Antibody Immunoprotectant for Category B Toxins | 000 | 5 | NIH | 11/30/2018 | -$219,062 |
| | 2019 | 2016 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI081392 | An SEB Immunoprotectant | 000 | 5 | NIH | 2/12/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $2,528,074 ) |
| | 2018 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI136272 | Development of highly potent human monoclonals for RSV immunoprophylaxis | 000 | 1 | NIH | 1/5/2018 | $300,000 |
| | 2018 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI141282 | Post-exposure immunotherapy for ricin exposure | 000 | 1 | NIH | 6/29/2018 | $298,015 |
| | 2018 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | SB1AI082744 | MR191_ An Immunoprotectant for Marburg Virus | 000 | 7 | NIH | 6/26/2018 | $1,000,000 |
| | 2018 | 2018 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R01AI111391 | An Immunoprotectant for Argentine Hemorrhagic Fever | 000 | 5 | NIH | 3/15/2018 | $1,022,916 |
| | 2018 | 2017 | Mapp Biopharmaceutical, Inc. | 6160 Lusk Blvd Ste 105 | San Diego | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 02 | 1 | CDC | 4/23/2018 | $0 |
| | 2018 | 2017 | Mapp Biopharmaceutical, Inc. | 6160 Lusk Blvd Ste 105 | San Diego | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 01 | 1 | CDC | 3/2/2018 | $0 |
| | 2018 | 2017 | Mapp Biopharmaceutical, Inc. | 6160 Lusk Blvd Ste 105 | San Diego | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 02 | 1 | CDC | 4/23/2018 | $0 |
| | 2018 | 2017 | Mapp Biopharmaceutical, Inc. | 6160 Lusk Blvd Ste 105 | San Diego | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 01 | 1 | CDC | 3/2/2018 | $0 |
| | 2018 | 2016 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R44AI082744 | An Immunoprotectant for Marburg Virus | 000 | 5 | NIH | 1/11/2018 | $0 |
| | 2018 | 2015 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI114069 | A human monoclonal for RSV prophylaxis | 000 | 2 | NIH | 11/21/2017 | -$48,440 |
| | 2018 | 2013 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | U01AI082276 | Monoclonal Immunoprotectants for Select Agents Toxins (Mab-SAT) | 000 | 5 | NIH | 1/12/2018 | -$44,417 |
|
| Issue Date FY: 2017 ( Subtotal = $2,485,703 ) |
| | 2017 | 2017 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R01AI111391 | An Immunoprotectant for Argentine Hemorrhagic Fever | 000 | 4 | NIH | 3/24/2017 | $1,029,383 |
| | 2017 | 2017 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI129082 | Direct sequencing of serum antibodies after infection | 000 | 1 | NIH | 1/17/2017 | $255,046 |
| | 2017 | 2017 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 000 | 1 | CDC | 8/28/2017 | $203,561 |
| | 2017 | 2017 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43IP001085 | Direct Sequencing of Antibodies of the Influenza Immune Response | 000 | 1 | CDC | 8/28/2017 | $21,439 |
| | 2017 | 2017 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | SB1AI082744 | MR191_ An Immunoprotectant for Marburg Virus | 000 | 6 | NIH | 5/1/2017 | $1,000,000 |
| | 2017 | 2016 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI126968 | Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis | 000 | 1 | NIH | 8/29/2017 | -$21,154 |
| | 2017 | 2015 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43AI115840 | Pseudomonas antibodies with designed glycans | 000 | 1 | NIH | 5/1/2017 | -$2,572 |
| | 2017 | 2014 | MAPP BIOPHARMACEUTICAL, INC. | 6160 LUSK BLVD STE 105 | SAN DIEGO | CA | 92121-2740 | SAN DIEGO | USA | R43CA186591 | Novel Immunotherapy for Brain Cancer | 000 | 1 | NIH | 6/15/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $3,801,182 ) (Continued on the next page) |
|
